Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that its two innovative drugs have been...
Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes
China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...
China’s Medical Insurance Payment Reform Achieves Nationwide Coverage, Faces Challenges Ahead
The first blue book on the reform of China’s medical insurance payment methods, titled “Report...
Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...
Hengrui Gains NMPA Approval for Phase III Study of SHR-8068 in PD-L1 Negative NSCLC
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical...
Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...
Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...
Shanghai Operation Robot Secures RMB 100 Million Series C Funding for AI-Driven Surgical Robot Development
Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100...
Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...
Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction
China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...
Broncus Medical Secures NMPA Approval for BroncAblate in Lung Cancer Treatment
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced...
Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871
Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...
Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...
HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...
Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...
Shanghai Healthcare Administration Pushes for 11th Round of VBP
Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...
Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance
Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...
Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria
France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...
Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China
US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...